Hims & Hers Health (NYSE:HIMS) Director Buys $1,172,732.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director David Wells acquired 48,400 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the acquisition, the director directly owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hims & Hers Health Price Performance

HIMS stock opened at $25.40 on Friday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The stock’s fifty day simple moving average is $24.03 and its 200-day simple moving average is $27.48. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $5.88 billion, a price-to-earnings ratio of -282.24, a price-to-earnings-growth ratio of 48.90 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same quarter in the previous year, the business posted $0.20 EPS. Hims & Hers Health’s revenue was up 3.8% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Director David Wells bought 48,400 shares for about $1.17 million, a sizable insider purchase that investors often read as a sign of confidence in the company’s outlook. Article Title
• Positive Sentiment: The company announced an expansion of Hims & Hers Benefits with eight new wellness partners, including brands tied to nutrition, fitness, women’s health, and metabolic monitoring, which may help strengthen subscriber engagement and improve the platform’s value proposition. Article Title
• Neutral Sentiment: Hims & Hers is pursuing global growth through the proposed acquisition of Australian telehealth platform Eucalyptus, using convertible notes to help fund the deal. The move could broaden the company’s market reach, but it may also raise dilution concerns for shareholders. Article Title
• Neutral Sentiment: Analysts continue to focus on Hims & Hers’ GLP-1 strategy and international expansion potential, but coverage remains mixed after the company missed earnings expectations last quarter and several firms kept hold/neutral-style ratings. Article Title
• Negative Sentiment: Bank of America cut its price target to $25 and warned that Hims & Hers’ 2026 outlook depends on a meaningful ramp in GLP-1 growth, highlighting execution risk around one of the company’s key growth drivers. Article Title

Analysts Set New Price Targets

A number of research analysts recently weighed in on HIMS shares. Leerink Partners lifted their target price on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. TD Cowen reduced their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Truist Financial lifted their target price on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $28.70.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Smartleaf Asset Management LLC boosted its position in shares of Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after buying an additional 283 shares during the period. W.G. Shaheen & Associates DBA Whitney & Co boosted its position in shares of Hims & Hers Health by 4.8% during the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock worth $436,000 after buying an additional 350 shares during the period. Sigma Planning Corp boosted its position in shares of Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after buying an additional 388 shares during the period. BAM Wealth Management LLC boosted its position in shares of Hims & Hers Health by 5.6% during the fourth quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after buying an additional 393 shares during the period. Finally, Xponance Inc. boosted its position in shares of Hims & Hers Health by 1.5% during the third quarter. Xponance Inc. now owns 28,195 shares of the company’s stock worth $1,599,000 after buying an additional 419 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.